[{"id":"44c07294-8489-4b3a-b2ed-b2c7e11ad982","acronym":"NCI#10057","url":"https://clinicaltrials.gov/study/NCT02978625","created_at":"2021-01-18T14:39:10.615Z","updated_at":"2025-02-25T13:48:20.165Z","phase":"Phase 2","brief_title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","source_id_and_acronym":"NCT02978625 - NCI#10057","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • ALK • NECTIN1","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["PD-L1 • ALK • NECTIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Imlygic (talimogene laherparepvec) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-21"},{"id":"fdf5903a-380e-4274-bdb7-c41fd2578d9b","acronym":"NCI-2022-03831","url":"https://clinicaltrials.gov/study/NCT05357794","created_at":"2022-05-03T15:54:14.202Z","updated_at":"2025-02-25T15:35:38.204Z","phase":"Phase 2","brief_title":"Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides","source_id_and_acronym":"NCT05357794 - NCI-2022-03831","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TNFRSF8 • CD4","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/13/2022","start_date":" 10/13/2022","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-10"},{"id":"fe033f7e-24b3-4288-bdd8-92b0259dd61d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05010005","created_at":"2021-08-18T15:53:40.772Z","updated_at":"2025-02-25T15:27:02.226Z","phase":"Phase 1","brief_title":"A Study of Ruxolitinib and Duvelisib in People With Lymphoma","source_id_and_acronym":"NCT05010005","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD8","pipe":" | ","alterations":" CD8 positive","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • Copiktra (duvelisib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 08/12/2021","start_date":" 08/12/2021","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-02-10"},{"id":"11565097-46a7-40c4-bd2e-84aac455986c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01638533","created_at":"2021-01-18T07:02:41.766Z","updated_at":"2025-02-25T14:33:33.086Z","phase":"Phase 1","brief_title":"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","source_id_and_acronym":"NCT01638533","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • AFP","pipe":"","alterations":" ","tags":["ER • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 08/03/2012","start_date":" 08/03/2012","primary_txt":" Primary completion: 11/29/2018","primary_completion_date":" 11/29/2018","study_txt":" Completion: 09/01/2020","study_completion_date":" 09/01/2020","last_update_posted":"2025-02-07"},{"id":"87dabab9-f6c0-480d-9545-b58a181a5845","acronym":"Keynote-D20","url":"https://clinicaltrials.gov/study/NCT04752826","created_at":"2021-02-12T13:55:59.801Z","updated_at":"2025-02-25T16:11:09.932Z","phase":"Phase 1/2","brief_title":"BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)","source_id_and_acronym":"NCT04752826 - Keynote-D20","lead_sponsor":"BioInvent International AB","biomarkers":" EGFR • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • BI-1808"],"overall_status":"Recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 01/25/2021","start_date":" 01/25/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 01/15/2028","study_completion_date":" 01/15/2028","last_update_posted":"2025-02-06"},{"id":"e4ee9c8a-52e5-4407-8d69-cf484bfda0df","acronym":"","url":"https://clinicaltrials.gov/study/NCT01352520","created_at":"2021-01-18T05:31:44.732Z","updated_at":"2025-02-25T16:43:37.647Z","phase":"Phase 2","brief_title":"SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)","source_id_and_acronym":"NCT01352520","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive • TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive • TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-02-05"},{"id":"298abb45-c0c1-474a-92b4-e2c5f74e7ea2","acronym":"PORT","url":"https://clinicaltrials.gov/study/NCT03385226","created_at":"2023-12-06T20:15:44.691Z","updated_at":"2025-02-25T16:07:22.758Z","phase":"Phase 2","brief_title":"A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)","source_id_and_acronym":"NCT03385226 - PORT","lead_sponsor":"University College, London","biomarkers":" HMGB1","pipe":" | ","alterations":" PD-L1 expression","tags":["HMGB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 01/15/2019","start_date":" 01/15/2019","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-12-09"},{"id":"7f0af447-6321-4676-bc15-187ae676dc07","acronym":"","url":"https://clinicaltrials.gov/study/NCT03695471","created_at":"2025-02-26T08:55:09.240Z","updated_at":"2025-02-26T08:55:09.240Z","phase":"Phase 2","brief_title":"Pembrolizumab in Treating Patients with Stage IB-IV Mycosis Fungoides","source_id_and_acronym":"NCT03695471","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1 • CD8 • PD-1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • PD-1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 02/04/2020","start_date":" 02/04/2020","primary_txt":" Primary completion: 06/21/2023","primary_completion_date":" 06/21/2023","study_txt":" Completion: 10/08/2024","study_completion_date":" 10/08/2024","last_update_posted":"2024-12-09"},{"id":"cb1a79b5-e061-4b3c-834a-601d77043b7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02512497","created_at":"2021-01-18T12:08:16.611Z","updated_at":"2025-02-25T14:35:44.470Z","phase":"Phase 1","brief_title":"Romidepsin Maintenance After Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT02512497","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin) • fludarabine IV • busulfan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/08/2017","start_date":" 12/08/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-10-29"},{"id":"fdae9b28-c98e-424b-b904-db41eb7115d7","acronym":"KISS01","url":"https://clinicaltrials.gov/study/NCT06651203","created_at":"2025-02-26T15:11:32.230Z","updated_at":"2025-02-26T15:11:32.230Z","phase":"","brief_title":"Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study","source_id_and_acronym":"NCT06651203 - KISS01","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" CD4 • KIR3DL2 • DPP4","pipe":"","alterations":" ","tags":["CD4 • KIR3DL2 • DPP4"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 460","initiation":"Initiation: 11/01/2024","start_date":" 11/01/2024","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2029","study_completion_date":" 11/01/2029","last_update_posted":"2024-10-21"},{"id":"b4d402cb-9b95-4ade-8b2a-ba008e6e8258","acronym":"","url":"https://clinicaltrials.gov/study/NCT04234048","created_at":"2021-01-18T20:35:42.430Z","updated_at":"2024-07-02T16:34:26.824Z","phase":"Phase 1","brief_title":"Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04234048","lead_sponsor":"SciTech Development, LLC","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fenretinide nanoparticle (ST-001 nanoFenretinide)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-06-12"},{"id":"144749df-0a66-4aa2-9a78-56b647da62a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05313243","created_at":"2022-04-06T14:52:59.872Z","updated_at":"2025-02-25T16:17:33.219Z","phase":"Phase 2","brief_title":"Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma","source_id_and_acronym":"NCT05313243","lead_sponsor":"Yale University","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Adcetris (brentuximab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 07/10/2023","start_date":" 07/10/2023","primary_txt":" Primary completion: 04/30/2028","primary_completion_date":" 04/30/2028","study_txt":" Completion: 07/30/2028","study_completion_date":" 07/30/2028","last_update_posted":"2024-06-05"},{"id":"b8d254b3-f15e-4c07-822c-72a282b1d8ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT06120504","created_at":"2023-11-07T16:14:29.912Z","updated_at":"2024-07-02T16:35:00.615Z","phase":"Phase 1","brief_title":"A Safety Study of SGN-35T in Adults With Advanced Cancers","source_id_and_acronym":"NCT06120504","lead_sponsor":"Seagen Inc.","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 02/29/2024","start_date":" 02/29/2024","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 04/30/2030","study_completion_date":" 04/30/2030","last_update_posted":"2024-05-28"},{"id":"9f080730-10f3-4827-9835-a467ea9be664","acronym":"","url":"https://clinicaltrials.gov/study/NCT03829540","created_at":"2021-01-18T18:54:43.363Z","updated_at":"2024-07-02T16:35:02.093Z","phase":"Phase 1","brief_title":"CD4CAR for CD4+ Leukemia and Lymphoma","source_id_and_acronym":"NCT03829540","lead_sponsor":"Huda Salman","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ICG122"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/09/2020","start_date":" 07/09/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2037","study_completion_date":" 12/01/2037","last_update_posted":"2024-05-22"},{"id":"46916f3b-5fbd-4c36-80c3-e0c13441714b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05879458","created_at":"2023-05-30T14:05:08.419Z","updated_at":"2024-07-02T16:35:05.459Z","phase":"Phase 2","brief_title":"Ritlecitinib in CTCL","source_id_and_acronym":"NCT05879458","lead_sponsor":"Icahn School of Medicine at Mount Sinai","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Litfulo (ritlecitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/17/2023","start_date":" 05/17/2023","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-05-07"},{"id":"f1ccd897-fa87-4dc4-b81e-968077056ea4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02840747","created_at":"2021-01-18T13:56:38.730Z","updated_at":"2024-07-02T16:35:06.284Z","phase":"","brief_title":"Tissue Repository: CTCL Collection Protocol","source_id_and_acronym":"NCT02840747","lead_sponsor":"Columbia University","biomarkers":" CD8 • CD4 • CD7 • DPP4","pipe":"","alterations":" ","tags":["CD8 • CD4 • CD7 • DPP4"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-05-02"},{"id":"5c8406ae-f056-4f83-9353-3927df966f6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04774068","created_at":"2021-02-26T12:55:20.808Z","updated_at":"2024-07-02T16:35:06.559Z","phase":"Phase 1","brief_title":"Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas","source_id_and_acronym":"NCT04774068","lead_sponsor":"Walter Hanel","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Istodax (romidepsin) • parsaclisib (INCB50465)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-01"},{"id":"b5d237d9-2e35-4f25-8d94-e3921b32c0ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT00888927","created_at":"2021-01-29T06:59:27.729Z","updated_at":"2024-07-02T16:35:07.654Z","phase":"Phase 1/2","brief_title":"Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT00888927","lead_sponsor":"Kyowa Kirin Co., Ltd.","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Poteligeo (mogamulizumab-kpkc)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 05/01/2009","start_date":" 05/01/2009","primary_txt":" Primary completion: 09/01/2012","primary_completion_date":" 09/01/2012","study_txt":" Completion: 09/01/2012","study_completion_date":" 09/01/2012","last_update_posted":"2024-04-25"},{"id":"ee293ead-e57f-4fa8-ae3c-c18f3cdf73ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT06382844","created_at":"2024-04-24T14:03:46.393Z","updated_at":"2024-07-02T16:35:07.577Z","phase":"","brief_title":"Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL","source_id_and_acronym":"NCT06382844","lead_sponsor":"Instituto de Investigación Biomédica de Salamanca","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-04-25"},{"id":"1bee75b3-9c2d-44df-aa38-d77483458e28","acronym":"","url":"https://clinicaltrials.gov/study/NCT02690545","created_at":"2021-01-17T17:19:13.271Z","updated_at":"2024-07-02T16:35:08.192Z","phase":"Phase 1/2","brief_title":"Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL","source_id_and_acronym":"NCT02690545","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TT11 • ATLCAR.CD30 cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/26/2016","start_date":" 08/26/2016","primary_txt":" Primary completion: 08/26/2025","primary_completion_date":" 08/26/2025","study_txt":" Completion: 08/26/2040","study_completion_date":" 08/26/2040","last_update_posted":"2024-04-23"},{"id":"1e1f1982-bd28-4ad1-b264-11dd83d52229","acronym":"","url":"https://clinicaltrials.gov/study/NCT02663297","created_at":"2021-01-18T12:58:42.532Z","updated_at":"2024-07-02T16:35:08.127Z","phase":"Phase 1","brief_title":"Administration of T Lymphocytes for Prevention of Relapse of Lymphomas","source_id_and_acronym":"NCT02663297","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression • ALK negative • TNFRSF8 negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression • ALK negative • TNFRSF8 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TT11 • ATLCAR.CD30 cell therapy"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 07/15/2016","start_date":" 07/15/2016","primary_txt":" Primary completion: 01/15/2021","primary_completion_date":" 01/15/2021","study_txt":" Completion: 01/01/2037","study_completion_date":" 01/01/2037","last_update_posted":"2024-04-23"},{"id":"d5dbb47e-aad4-4309-8d8b-fc01d9f10ce9","acronym":"LCCC 1606-ATL","url":"https://clinicaltrials.gov/study/NCT03602157","created_at":"2021-01-18T17:42:37.765Z","updated_at":"2024-07-02T16:35:08.204Z","phase":"Phase 1","brief_title":"Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL","source_id_and_acronym":"NCT03602157 - LCCC 1606-ATL","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8 • CCR4","pipe":" | ","alterations":" TNFRSF8 positive • TNFRSF8 expression","tags":["TNFRSF8 • CCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive • TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bendamustine • fludarabine IV • TT11 • ATLCAR.CD30.CCR4 cells"],"overall_status":"Recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2041","study_completion_date":" 09/30/2041","last_update_posted":"2024-04-23"},{"id":"498a1e42-e7ba-4c45-b9ea-df2809619942","acronym":"","url":"https://clinicaltrials.gov/study/NCT04074746","created_at":"2021-01-18T19:57:28.222Z","updated_at":"2024-07-02T16:35:08.805Z","phase":"Phase 1/2","brief_title":"Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas","source_id_and_acronym":"NCT04074746","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • acimtamig (AFM13) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/18/2020","start_date":" 07/18/2020","primary_txt":" Primary completion: 04/15/2025","primary_completion_date":" 04/15/2025","study_txt":" Completion: 04/15/2025","study_completion_date":" 04/15/2025","last_update_posted":"2024-04-18"},{"id":"e4a4b657-550e-4739-b71c-fff75613dfbe","acronym":"ETCTN 10500","url":"https://clinicaltrials.gov/study/NCT05627245","created_at":"2022-11-25T15:58:14.707Z","updated_at":"2024-07-02T16:35:09.644Z","phase":"Phase 1","brief_title":"Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment","source_id_and_acronym":"NCT05627245 - ETCTN 10500","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EZH2","pipe":" | ","alterations":" RAS wild-type • EZH2 mutation • EZH2 wild-type","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • EZH2 mutation • EZH2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat) • Beleodaq (belinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-04-15"}]